Is the fixed-dose combination of telmisartan and hydrochlorothiazide a good approach to treat hypertension?

Abstract

Blockade of the renin-angiotensin system with selective AT₁ receptor antagonists is recognized as an effective mean to lower blood pressure in hypertensive patients. Among the class of AT₁ receptor antagonists, telmisartan offers the advantage of a very long half-life. This enables blood pressure control over 24 hours using once-daily administration. The combination of telmisartan with hydrochlorothiazide is a logical step because numerous previous studies have demonstrated that sodium depletion enhances the antihypertensive efficacy of drugs interfering with the activity of the renin-angiotensin system (RAS). In accordance with past experience using similar compounds blocking the RAS, several controlled studies have now demonstrated that the fixed-dose combination of telmisartan/hydrochlorothiazide is superior in lowering blood pressure than either telmisartan or hydrochlorothiazide alone. Of clinical interest also is the observation that the excellent clinical tolerance of the angiotensin II receptor antagonist is not affected by the association of the low-dose thiazide. Thus telmisartan/hydrochlorothiazide is an effective and well-tolerated antihypertensive combination. Finally, the development of fixed-dose combinations should improve drug adherence because of the one-pill-a-day regimen.

Keywords:

• telmisartan
• hydrochlorothiazide
• fixed-dose combinations
• antihypertensive agent
• safety
• compliance